VEMERIX Report Details Mesotherapy Consumable Costs and 2026 Sourcing Rules
A VEMERIX analysis of 15.3 million procedures reveals up to 330x markups on single-use tips. A new Chinese regulation requires delivery needles to have their own registration.
An in-depth analysis by VEMERIX of 15.3 million injectable procedures has uncovered significant cost markups on mesotherapy consumables. The report indicates that markups on single-use tips can reach as high as 330 times their original cost.
The research focused on the supply chain and cost structure of injectable treatments, highlighting how small components contribute substantially to overall expenses due to high margins. This deep dive into the cost of goods provides insight into the economics of aesthetic treatments.
Furthermore, the report details a new Chinese regulation set to take effect in 2026. This forthcoming rule mandates that delivery needles used in injectable devices must carry their own specific registration. This regulatory change is expected to reshape the sourcing landscape for injector devices globally.
VEMERIX aims to bring transparency to the true cost of medical consumables and assist industry stakeholders in navigating evolving regulatory environments. The company seeks to promote efficiency and cost-effectiveness in the procurement of medical devices.